Free tool
Oncology stocks
We cover 36 companies grouped under the Oncology theme. The median market value in the group is $57.64M. Across the group, the median move over the past trading day is 0.00%. 36% of the 36 with a 200-day average trade above it. Price change over the past year runs from −79.8% to +46.3% across the middle 80 percent of the group, with a median of −28.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
36 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% | Oct 29, 2026 |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $71.92B | Large cap | +9.97% | Oct 27, 2026 |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% | Nov 4, 2026 |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% | Nov 5, 2026 |
| 4568.T | Daiichi Sankyo Company, Limited | $33.43B | Large cap | −14.83% | Oct 30, 2026 |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% | Nov 3, 2026 |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% | Oct 27, 2026 |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% | Nov 5, 2026 |
| GE9.DE | Genmab A/S | $20.71B | Large cap | −12.96% | Nov 5, 2026 |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% | Oct 27, 2026 |
| SMMT | Summit Therapeutics Inc. | $11.35B | Large cap | −42.63% | Oct 19, 2026 |
| OSE.PA | OSE Immunotherapeutics SA | $90.43M | Micro cap | −46.85% | Sep 28, 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | $84.35M | Micro cap | −13.25% | Nov 13, 2026 |
| OSTX | OS Therapies Incorporated | $76.68M | Micro cap | −34.00% | Nov 16, 2026 |
| CRDF | Cardiff Oncology, Inc. | $76.56M | Micro cap | −54.65% | Nov 12, 2026 |
| PLRX | Pliant Therapeutics, Inc. | $73.69M | Micro cap | −31.36% | Nov 5, 2026 |
| PMVP | PMV Pharmaceuticals, Inc. | $70.03M | Micro cap | −7.75% | Nov 16, 2026 |
| HRTX | Heron Therapeutics, Inc. | $59.27M | Micro cap | −77.04% | Nov 3, 2026 |
| IMMP | Immutep Limited | $56.00M | Micro cap | −77.11% | Sep 2, 2026 |
| CANTA.ST | Cantargia AB (publ) | $50.41M | Micro cap | −26.48% | Nov 25, 2026 |
| HOWL | Werewolf Therapeutics, Inc. | $48.05M | Micro cap | −25.65% | Oct 30, 2026 |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $44.46M | Micro cap | −74.90% | Nov 3, 2026 |
| KYNB | Kyntra Bio, Inc. | $32.82M | Micro cap | −22.66% | Nov 9, 2026 |
| MDNA.TO | Medicenna Therapeutics Corp. | $31.26M | Micro cap | −56.48% | Nov 12, 2026 |
| 4582.T | SymBio Pharmaceuticals Limited | $31.19M | Micro cap | −56.46% | Oct 29, 2026 |
| BYSI | BeyondSpring Inc. | $28.37M | Micro cap | −62.09% | Nov 12, 2026 |
| LTRN | Lantern Pharma Inc. | $27.87M | Micro cap | −46.17% | Nov 11, 2026 |
| CLRB | Cellectar Biosciences, Inc. | $24.01M | Micro cap | −47.30% | Nov 12, 2026 |
| BFRI | Biofrontera Inc. | $22.72M | Micro cap | +77.91% | Nov 11, 2026 |
| TPST | Tempest Therapeutics, Inc. | $17.86M | Micro cap | −89.96% | Nov 5, 2026 |
| LSTA | Lisata Therapeutics, Inc. | $15.68M | Micro cap | −30.40% | Nov 5, 2026 |
| PDSB | PDS Biotechnology Corporation | $12.49M | Micro cap | −82.56% | Nov 12, 2026 |
| BLRX | BioLineRx Ltd. | $11.79M | Micro cap | −26.63% | Aug 31, 2026 |
| LNAI | Lunai Bioworks Inc. | $9.97M | Micro cap | −89.34% | Sep 28, 2026 |
| BCAB | BioAtla, Inc. | $5.20M | Micro cap | −86.04% | Nov 12, 2026 |
| CRIS | Curis, Inc. | $3.86M | Micro cap | −5.52% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.